Jiang Hanfang, Li Huiping
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, No. 52nd Fucheng Road, Haidian District, Beijing, 100142, China.
BMC Cancer. 2021 Feb 10;21(1):149. doi: 10.1186/s12885-021-07860-2.
Breast cancer (BC) is a leading cause of cancer-related death in females worldwide. Previous studies have demonstrated that matrix metalloproteinases (MMPs) play key roles in metastasis and are associated with survival in various cancers. The prognostic values of MMP2 and MMP9 expression in BC have been investigated, but the results remain controversial. Thus, we performed the present meta-analysis to investigate the associations between MMP2/9 expressions in tumor cells with clinicopathologic features and survival outcome in BC patients.
Eligible studies were searched in PubMed, Web of Science, EMBASE, CNKI and Wanfang databases. The associations of MMP2/9 overexpression in tumor cells with overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS) were assessed by hazard ratio (HR) and 95% confidence interval (CI). The associations of MMP2/9 overexpression with clinicopathological features were investigated by calculating odds ratio (OR) and 95% CI. Subgroup analysis, sensitivity analysis, meta-regression, and analysis for publication bias were performed.
A total of 41 studies comprising 6517 patients with primary BC were finally included. MMP2 overexpression was associated with an unfavorable OS (HR = 1.60, 95% CI 1.33 -1.94, P < 0.001) while MMP9 overexpression predicted a shorter OS (HR = 1.52, 95% CI 1.30 -1.77, P < 0.001). MMP2 overexpression conferred a higher risk to distant metastasis (OR = 2.69, 95% CI 1.35-5.39, P = 0.005) and MMP9 overexpression correlated with lymph node metastasis (OR = 2.90, 95% CI 1.86 - 4.53, P < 0.001). Moreover, MMP2 and MMP9 overexpression were both associated with higher clinical stage and histological grade in BC patients. MMP9 overexpression was more frequent in patients with larger tumor sizes.
Tumoral MMP2 and MMP9 are promising markers for predicting the prognosis in patients with BC.
乳腺癌（BC）是全球女性癌症相关死亡的主要原因。先前的研究表明，基质金属蛋白酶（MMPs）在转移中起关键作用，并与多种癌症的生存相关。已对BC中MMP2和MMP9表达的预后价值进行了研究，但结果仍存在争议。因此，我们进行了本荟萃分析，以研究肿瘤细胞中MMP2/9表达与BC患者临床病理特征及生存结局之间的关联。
在PubMed、Web of Science、EMBASE、CNKI和万方数据库中检索符合条件的研究。通过风险比（HR）和95%置信区间（CI）评估肿瘤细胞中MMP2/9过表达与总生存（OS）、无病生存（DFS）和无复发生存（RFS）的关联。通过计算比值比（OR）和95%CI研究MMP2/9过表达与临床病理特征的关联。进行亚组分析、敏感性分析、荟萃回归和发表偏倚分析。
最终纳入41项研究，共6517例原发性BC患者。MMP2过表达与不良OS相关（HR = 1.60，95%CI 1.33 - 1.94，P < 0.001），而MMP9过表达预示着较短的OS（HR = 1.52，95%CI 1.30 - 1.77，P < 0.001）。MMP2过表达使远处转移风险更高（OR = 2.69，95%CI 1.35 - 5.39，P = 0.005），MMP9过表达与淋巴结转移相关（OR = 2.90，95%CI 1.86 - 4.53，P < 0.001）。此外，MMP2和MMP9过表达均与BC患者的更高临床分期和组织学分级相关。MMP9过表达在肿瘤较大的患者中更常见。
肿瘤MMP2和MMP9是预测BC患者预后的有前景的标志物。
Zotero 插件
